A phase II study of menogaril in low-grade non-Hodgkin's lymphoma. An NCI Canada Clinical Trials Group study

Area of Science:

• Oncology
• Clinical Pharmacology

Background:

• Low-grade non-Hodgkin's lymphoma (NHL) requires effective treatment options.
• Novel chemotherapeutic agents are continually investigated for NHL.
• Menogaril is an anthracycline antibiotic with potential antineoplastic activity.

Purpose of the Study:

• To evaluate the efficacy and toxicity of menogaril in patients with low-grade non-Hodgkin's lymphoma.
• To determine the response rate of menogaril in a previously untreated patient cohort.

Main Methods:

• A phase II clinical trial was conducted by the NCI Canada Clinical Trials Group.
• Menogaril was administered intravenously every 4 weeks.
• Twenty-six eligible patients with low-grade non-Hodgkin's lymphoma were enrolled.

Main Results:

• Partial responses were observed in 9 out of 26 eligible patients (35% response rate).
• Fifteen patients had not received prior therapy.
• Moderate toxicities were reported, including myelosuppression, nausea, phlebitis, alopecia, and lethargy.

Conclusions:

• Menogaril demonstrated modest activity in the treatment of low-grade non-Hodgkin's lymphoma.
• The observed toxicity profile suggests a need for careful patient monitoring.
• Further investigation may be warranted for specific patient subgroups or combination therapies.